Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Lancet. 2005 Jan 15-21;365(9455):241-52.

    Porphyrias.

    Source

    Research Program in Molecular Medicine, Biomedicum-Helsinki, University of Helsinki, Finland. raili.kauppinen@hus.fi

    Abstract

    Seven different porphyrias form a group of inherited metabolic disorders, each resulting from a partial deficiency of a specific enzyme in the haem biosynthesis pathway. Clinically, the three most important entities are an acute porphyric attack and acute and chronic skin symptoms. Porphyrias are rare and sometimes misdiagnosed, because various symptoms and signs mimic other diseases. Once porphyria is suspected, biochemical analyses easily detect porphyrins and their precursors from blood, urine, or faeces. Mutation screening can be done at the quiescent phase of the disease. Pathogenetic mechanisms and clinical manifestations differ in individual porphyrias and most of them require a specific treatment. Early diagnosis and information about precipitating factors can diminish mortality and prevent subsequent attacks among patients with acute porphyrias, so mutation screening is recommended for family members.

    Comment in

    • More on porphyrias. [Lancet. 2005]
    • More on porphyrias. [Lancet. 2005]
    PMID:
    15652607
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      Recent activity

      • Porphyrias.
        Porphyrias.
        Lancet. 2005 Jan 15-21 ;365(9455):241-52.
        PubMed

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk